263 related articles for article (PubMed ID: 32647152)
1. Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
Eren OE; Gaul C; Peikert A; Gendolla A; Ruscheweyh R; Straube A
Sci Rep; 2020 Jul; 10(1):11382. PubMed ID: 32647152
[TBL] [Abstract][Full Text] [Related]
2. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
3. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
5. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
[TBL] [Abstract][Full Text] [Related]
6. Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment.
Durham PL; Masterson CG
Headache; 2013 Jan; 53(1):67-80. PubMed ID: 23095108
[TBL] [Abstract][Full Text] [Related]
7. Management of acute and chronic migraine.
Coppola G; Schoenen J
Curr Opin Support Palliat Care; 2012 Jun; 6(2):177-82. PubMed ID: 22406987
[TBL] [Abstract][Full Text] [Related]
8. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
[TBL] [Abstract][Full Text] [Related]
9. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
[TBL] [Abstract][Full Text] [Related]
10. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
[TBL] [Abstract][Full Text] [Related]
11. Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry.
Ruscheweyh R; Gossrau G; Dresler T; Freilinger T; Förderreuther S; Gaul C; Kraya T; Neeb L; Ruschil V; Straube A; Scheidt J; Jürgens TP
J Headache Pain; 2023 Oct; 24(1):135. PubMed ID: 37817093
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
13. CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA.
Moreno-Mayordomo R; Ruiz M; Pascual J; Gallego de la Sacristana M; Vidriales I; Sobrado M; Cernuda-Morollon E; Gago-Veiga AB; Garcia-Azorin D; Telleria JJ; Guerrero AL
J Headache Pain; 2019 Apr; 20(1):39. PubMed ID: 31014225
[TBL] [Abstract][Full Text] [Related]
14. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.
Link AS; Kuris A; Edvinsson L
J Headache Pain; 2008 Feb; 9(1):5-12. PubMed ID: 18217201
[TBL] [Abstract][Full Text] [Related]
15. Chronic migraine: a therapeutic challenge for clinicians.
Irimia P; Carmona-Abellán M; Martínez-Vila E
Expert Opin Emerg Drugs; 2012 Dec; 17(4):445-7. PubMed ID: 22998764
[TBL] [Abstract][Full Text] [Related]
16. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
17. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
[TBL] [Abstract][Full Text] [Related]
18. Association between response to triptans and response to erenumab: real-life data.
Frattale I; Caponnetto V; Casalena A; Assetta M; Maddestra M; Marzoli F; Affaitati G; Giamberardino MA; Viola S; Gabriele A; Pistoia F; Cerone D; Marini C; Sacco S; Ornello R
J Headache Pain; 2021 Jan; 22(1):1. PubMed ID: 33407070
[TBL] [Abstract][Full Text] [Related]
19. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
[TBL] [Abstract][Full Text] [Related]
20. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes.
Talbot J; Stuckey R; Crawford L; Weatherby S; Mullin S
J Headache Pain; 2021 Jan; 22(1):5. PubMed ID: 33421995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
